Arpita Dutt
Zacks.com
Contact Arpita
Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
| Recent: |
|
| Past: |
|
Past articles by Arpita:
5 Leisure & Travel Stocks to Benefit from Thanksgiving Vacation Plans
According to AAA, almost 51M Americans will travel this Thanksgiving - here is a look at five leisure and travel stocks including SkyWest (SKYW) set to benefit during this holiday season. → Read More
Is a CVS Health (CVS) - Aetna (AET) Deal in the Cards?
Is an e-commerce company's interest in entering the drug pharmacy space the reason behind CVS Health's (CVS) interest in acquiring Aetna? → Read More
3 Biotech and Pharma Stocks with Key FDA Catalysts this October
Here is a look at three biotech and pharma stocks including Flexion (FLXN) that have an important regulatory event lined up this month. → Read More
5 Top-Ranked Biotech Stocks to Buy Right Now
If you are looking to invest in the biotech sector, here is a peek at 5 buy-ranked biotech stocks including Regeneron Pharmaceuticals (REGN). → Read More
Better Days Ahead for the Pharma Sector?
Sales, R&D, strong results, and a higher number of FDA approvals. → Read More
Allergan Tops on Q3 Earnings, Revenues Shoot Up Y/Y
Botox maker, Allergan (AGN) surpassed earnings expectations by a wide margin with revenues shooting up 90% from the year-ago period. → Read More
Will Allergan (AGN) Surprise with an Earnings Beat in 3Q?
Investor focus will remain on any updates on a possible deal with Pfizer and on Allergan's (AGN) R&D day. → Read More
AbbVie Tops on 3Q Earnings & Revenues, Ups 2015 View
It was a "beat and raise" quarter for AbbVie (ABBV), which also provided its outlook for 2016. → Read More
Will AbbVie (ABBV) Surprise on Earnings Again in Q3?
Focus on AbbVie's (ABBV) third quarter call will be on the performance of key drugs - Humira, Viekira Pak and Imbruvica. → Read More
Merck Tops on Q3 Earnings, Revenues Miss; Raises Outlook
Merck's (MRK) third quarter earnings once again surpassed expectations despite the presence of currency headwinds. → Read More
Will Tecfidera Slowdown Hit Biogen (BIIB) Earnings in Q3?
Will Biogen (BIIB) miss third quarter expectations due to the slowdown in Tecfidera sales? → Read More